Testicular Germ Cell Tumors and Molecular Biomarkers

miR-371a-3p is approaching clinical use as a noninvasive diagnostic marker for testicular germ cell tumors

Journal: Current Opinion in Urology | Published: 2025-10-22 | Type: Review | PMID: 41128509 Authors: Oliveira-Lopes B, Tavares NT, Lobo J — Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP), Portuguese Oncology Institute, Porto Funding/COI: Not disclosed

Summary

Testicular germ cell tumors (TGCTs) are the most common solid malignancies in males aged 15–35, and while cure rates are high, the field still wrestles with overtreatment and an inability to reliably predict who will relapse or resist cisplatin. This narrative review surveys the current landscape of molecular biomarkers — microRNAs, immunohistochemistry markers, and circulating tumor DNA — that researchers hope will replace or supplement classical serum markers like AFP and hCG. The headline finding is that one microRNA, miR-371a-3p, has accumulated enough evidence to be close to clinical implementation.

Claims

• miR-371a-3p has demonstrated high sensitivity and specificity across multiple studies and is positioned to enter clinical routine
• FOXA2 is an emerging immunohistochemistry marker for diagnosing yolk sac tumor, a histological subtype that current markers struggle to identify
• Circulating tumor DNA (ctDNA) shows promise for minimal residual disease (MRD) detection — identifying lingering cancer after treatment — but remains less accurate than miR-371a-3p
• Existing classical serum markers (AFP, hCG, LDH) perform poorly for early-stage disease and cannot detect teratoma, which is clinically important because teratoma is chemotherapy-resistant
• The authors identify relapse prediction and teratoma detection as the highest-priority unsolved problems in the field

Study Quality

This is a narrative review published in a specialty opinion journal, which carries significant weight as a summary of expert consensus but has no formal systematic methodology. There is no PRISMA statement, no described search strategy, no quality assessment of included studies, and no meta-analytic synthesis. It synthesizes the state of the field rather than generating new evidence.

The authors are affiliated with a single Portuguese oncology research center specializing in cancer biology and epigenetics. That focus is relevant — they're not generalist urologists offering a bird's-eye view, but researchers embedded in the biomarker literature. That can mean deeper expertise or narrower perspective depending on what they emphasize and omit.

Red Flags

• No systematic search methodology described — selection of included studies is opaque and potentially biased toward work the authors know
• Funding and conflicts of interest are not disclosed, which is a notable gap for a review covering commercially relevant diagnostic technologies
• No sample sizes or effect estimates are reported in the abstract for individual studies; the claims of "high sensitivity and specificity" for miR-371a-3p are not quantified here
• "Approaching clinical implementation soon" is a phrase that has appeared in the biomarker literature for years — the review does not clarify what regulatory or validation milestones remain
• Narrative reviews in opinion journals are inherently susceptible to cherry-picking; without a full read, the scope of evidence presented cannot be verified

Strengths

• Covers multiple biomarker modalities in a single paper (miRNAs, IHC, ctDNA), giving a useful map of the field
• Correctly identifies clinically meaningful unmet needs — teratoma detection and relapse prediction — rather than just cataloguing markers for the sake of it
• miR-371a-3p's trajectory is well-documented in the literature; multiple independent groups have replicated its diagnostic utility, lending credibility to the authors' assessment
• The review is recent (October 2025), reflecting current evidence

Verdict

This is a useful orientation paper for anyone wanting to understand where testicular cancer biomarker research stands in late 2025 — but it is an expert opinion piece, not a systematic analysis. The core claim, that miR-371a-3p is the most clinically mature noninvasive biomarker for TGCTs, is well-supported in the broader literature even if this review doesn't quantify it. Treat the paper as a curated overview, not a definitive evidence synthesis. The undisclosed funding and COI are a minor but real concern for a field where diagnostics have commercial value. Read it for the roadmap; go to the primary studies for the numbers.